Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹340 Cr revenue.
COGS 54.5%, employees 14.6%.
| KPI | Company | Sector Median |
|---|---|---|
| ROE | -6.6%▼ | 10.5% |
| ROCE | -1.7%▼ | 13.8% |
| Net Margin | -6.1%▼ | 8.7% |
| EBITDA Margin | 7.5%▼ | 16.0% |
| Debt To Equity | 0.39x▲ | 0.21x |
| Rev Growth 3yr | 17.0%▲ | 5.8% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹350 Cr +2.8% | ₹340 Cr +32.3% | ₹257 Cr +18.1% | ₹218 Cr +2.8% | ₹212 Cr +3.6% | ₹205 Cr -10.3% | ₹228 Cr +3.9% | ₹220 Cr |
| Other Income | ₹8 Cr -31.8% | ₹12 Cr +38.5% | ₹9 Cr -26.8% | ₹12 Cr +50.9% | ₹8 Cr -10.4% | ₹9 Cr -24.4% | ₹11 Cr -9.6% | ₹13 Cr |
| Total Income | ₹358 Cr +1.6% | ₹352 Cr +32.5% | ₹266 Cr +15.8% | ₹230 Cr +4.5% | ₹220 Cr +3.0% | ₹213 Cr -11.0% | ₹240 Cr +3.2% | ₹232 Cr |
| COGS | ₹182 Cr -2.1% | ₹185 Cr +17.1% | ₹158 Cr +15.2% | ₹137 Cr +1.0% | ₹136 Cr +1.3% | ₹134 Cr -9.8% | ₹149 Cr +6.0% | ₹140 Cr |
| ₹379 Cr -1.8% | ₹386 Cr +56.2% | ₹247 Cr +19.9% | ₹206 Cr +7.4% | ₹192 Cr +3.1% | ₹186 Cr -10.0% | ₹207 Cr +4.7% | ₹198 Cr | |
| Profit Before Tax | (₹21 Cr) +37.1% | (₹34 Cr) ↓ Decline | ₹19 Cr -20.5% | ₹24 Cr -15.5% | ₹28 Cr +2.8% | ₹27 Cr -17.3% | ₹33 Cr -5.2% | ₹35 Cr |
| ₹7 Cr -23.6% | ₹9 Cr +12.0% | ₹8 Cr +5.1% | ₹8 Cr +10.7% | ₹7 Cr +3.8% | ₹7 Cr -21.3% | ₹9 Cr -35.2% | ₹13 Cr | |
| Net Profit | (₹29 Cr) +34.5% | (₹44 Cr) ↓ Decline | ₹11 Cr -33.1% | ₹16 Cr -24.5% | ₹21 Cr +2.5% | ₹20 Cr -15.9% | ₹24 Cr +13.7% | ₹21 Cr |
| Profit (Owners) | (₹22 Cr) +49.8% | (₹44 Cr) ↓ Decline | ₹11 Cr -36.0% | ₹16 Cr -21.9% | ₹21 Cr +3.2% | ₹20 Cr -15.6% | ₹24 Cr +13.7% | ₹21 Cr |
| Minority Interest | (₹7 Cr) | ₹0.00 Cr | ₹0.00 Cr +100.0% | (₹0.68 Cr) -183.3% | (₹0.24 Cr) -242.9% | (₹0.07 Cr) | ₹0.00 Cr | ₹0.00 Cr |
| Other Comprehensive Income | ₹0.70 Cr +252.1% | ₹0.20 Cr ↑ Recovery | (₹0.20 Cr) ↓ Decline | ₹0.04 Cr ↑ Recovery | (₹0.23 Cr) ↓ Decline | ₹0.16 Cr +300.0% | ₹0.04 Cr ↑ Recovery | (₹0.09 Cr) |
| EPS | (₹31.82) | (₹63.38) | ₹18.08 | ₹28.47 | ₹36.45 | ₹35.59 | ₹42.17 | ₹37.08 |
| Diluted Shares | ₹0.69 Cr | ₹0.69 Cr | ₹0.58 Cr | ₹0.58 Cr | ₹0.58 Cr | ₹0.57 Cr | ₹0.57 Cr | ₹0.57 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclosure under regulation 7(2) of SEBI (PIT) Regulations, 2015.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Desai Shares & Stocks Pvt Ltd
Please find the enclosed newspaper notice to the physical Shareholders informing them about the special Window for re lodge the transfer deed.
Annual Secretarial Compliance report for the Year ended March 31, 2026, Pursuant to regulations 24A of SEBI (LODR) Regulations, 2015.
Newspaper publication of Audited Financial Results of the Quarter and Year ended on March 31, 2026.
Transcript of Earning Conference Call of Q4FY26.
Intimation of Q4FY26 and FY26 Earnings Conference Call.
Bharat Parenterals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/05/2026 ,inter alia, to consider and approve The standalone and consolidated .... Bh...
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</...
Newspaper Advertisement Under Regulation 30 of SEBI LODR (Listing Obligations and Disclosure Requirements), Regulations 2015.
Outcome of the U.S. FDA Inspection at Innoxel Lifesciences Private Limited subsidiary Company of Bharat Parenterals Limited
Intimation for the closure of the trading window in terms of SEBI (Prohibition of Insider Trading ) Regulations, 2015.
Please find the enclosed newspaper notice to physical shareholders informing them about the special window to re-lodge the transfer deed.
Outcome of Board Meeting held on January 30, 2026.
Bharat Parenterals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2026 ,inter alia, to consider and approve Unaudited Financial Results .... Bharat...
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.